News und Analysen
Roche: Nach ersten sechs Monaten auf Kurs
Actelion: Die Gewinne steigen und steigen
Novartis: Der Konzerngewinn droht zu schrumpfen
Roche: Dieses Produkt ist absolut konkurrenzlos!
Novartis: Trendwende verschoben?
MorphoSys: Empfindliche Schlappe, aber noch kein Grund zur Panik?
Morphosys: Ist jetzt die Zeit für schnelle GEWINNE?
Novartis: die Konkurrenz schläft NICHT!
MorphoSys AG: Bad News sorgen für heftigen Kurseinbruch…
2 Magnificent Dividend Stocks to Hold for the Next Decade
There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from
Why Novartis Stock Topped the Market on Tuesday
Scooting past analyst estimates for its latest quarter gave Novartis (NYSE: NVS) a lift on Tuesday. Investors like what they heard about the global healthcare company's inaugural earnings release
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Novartis Ag (NYSE: NVS)Q1 2024 Earnings CallApr 23, 2024, 8:00 a.m. ET
Operator
Source Fool.com
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its
Why Roche Holdings Stock Popped Today
Shares of Swiss pharmaceuticals giant Roche Holdings (OTC: RHHBY) stock popped 2.5% in early trading Thursday before giving back about half of its gains.
Roche announced this morning that the U.S
1 Magnificent Dividend Stock to Buy and Hold
There are plenty of dividend stocks on the market. However, some raise their payouts irregularly, while others don't have businesses that look robust enough to support payout growth for a long time
Harvard Business Professor on Failing Well
In this podcast, Motley Fool host Deidre Woollard talks about the art of failing with Amy Edmondson, the Novartis Professor of Leadership and Management at the Harvard Business School, and author of
Novartis Ag (NVS) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Novartis Ag (NYSE: NVS)Q4 2023 Earnings CallJan 31, 2024, 8:00 a.m. ET
Operator
Source Fool.com
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know
In late November, Roche's (OTC: RHHBY) subsidiary Genentech and the chipmaker Nvidia (NASDAQ: NVDA) agreed to collaborate on developing new medicines using artificial intelligence (AI) over the next
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Healthcare companies are spending big on developing treatments for inflammatory bowel disease (IBD), which consists of either Crohn's disease or ulcerative colitis (UC), or both. The lure for IBD
2 Green Flags and 1 Red Flag for Novartis Stock
Share prices of Swiss pharmaceutical company Novartis (NYSE: NVS) have climbed more than 10% so far this year. The company focuses on cardiovascular, immunology, neuroscience, solid tumors, and
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Novartis Ag (NYSE: NVS)Q3 2023 Earnings CallOct 24, 2023, 8:00 a.m. ET
Operator
Source Fool.com
2 Biotech Stocks That Could Make You Richer
Although sometimes risky and volatile, the biotech industry is an excellent place to find stocks that can generate steady returns for years. That's because these companies tend to offer products
3 Unstoppable Stocks to Buy and Hold for Decades
Want to invest in stocks that you can buy and forget about? If so, you'll want to consider companies with plenty of long-term growth opportunities and solid financials. Among the best growth
2 Dividend Stocks to Buy and Hold Forever
Finding dividend stocks worth holding onto for good isn't an easy task. Investors shouldn't necessarily rely on a company's current dividend yield to make that decision. Recent history has shown